Table 2 Clinical outcomes of ATTAIN study patients with Staphylococcus aureus nosocomial pneumonia according to vancomycin trough levels
Vancomycin trough level (μg/mL), n/N (%) | p* | |||
|---|---|---|---|---|
< 10 | 10 to < 15 | ≥ 15 | ||
All patients | ||||
Clinical cure | 21/30 (70) | 18/33 (55) | 17/35 (49) | 0.09 |
MRSA | 13/20 (65) | 15/26 (58) | 16/30 (53) | 0.42 |
MRSA based on median trough levels collected up to study Day 4 | 14/26 (54) | 11/20 (55) | 8/16 (50) | 0.83 |
Any serious adverse event | 4/30 (13) | 8/33 (24) | 13/35 (37) | 0.03 |
Renal adverse events† | 0/30 (0) | 1/33 (3) | 6/35 (17) | <0.01 |
Significant increases in serum creatinine‡ | 0/30 (0) | 0/33 (0) | 4/35 (11) | 0.02 |
Increase 2 to < 3 times from baseline | 0/30 (0) | 0/33 (0) | 1/35 (3) | -- |
Increase ≥ 3 times from baseline | 0/30 (0) | 0/33 (0) | 3/35 (9) | -- |
Deaths | 3/30 (10) | 5/33 (15) | 7/35 (20) | 0.31 |
Median length of therapy in days (interquartile range) | 10 (6, 12) | 11 (8, 14) | 11 (8, 15) | 0.14¥ |
Excluding patients with ARF or vancomycin exposure within 7 days§ | ||||
Clinical cure | 12/17 (71) | 9/15 (60) | 3/11 (27) | 0.04 |
Any serious adverse event | 2/17 (12) | 3/15 (20) | 6/11 (55) | 0.02 |
Renal adverse events† | 0/17 (0) | 0/15 (0) | 3/11 (27) | 0.01 |
Significant increases in serum creatinine‡ | 0/17 (0) | 0/15 (0) | 2/11 (18) | 0.06 |
Deaths | 2/17 (12) | 3/15 (20) | 5/11 (45) | 0.07 |